Celon Pharma S.A. (WSE:CLN)
22.10
-1.00 (-4.33%)
Jun 13, 2025, 5:03 PM CET
Celon Pharma Revenue
Celon Pharma had revenue of 49.08M PLN in the quarter ending March 31, 2025, with 25.98% growth. This brings the company's revenue in the last twelve months to 215.11M, up 2.78% year-over-year. In the year 2024, Celon Pharma had annual revenue of 204.98M, down -4.18%.
Revenue (ttm)
215.11M
Revenue Growth
+2.78%
P/S Ratio
5.53
Revenue / Employee
379.38K
Employees
558
Market Cap
1.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 204.98M | -8.94M | -4.18% |
Dec 31, 2023 | 213.92M | 20.04M | 10.33% |
Dec 31, 2022 | 193.89M | -2.20M | -1.12% |
Dec 31, 2021 | 196.09M | 38.64M | 24.54% |
Dec 31, 2020 | 157.45M | 55.20M | 53.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NEUCA | 12.82B |
Synektik Spólka Akcyjna | 556.63M |
Voxel | 556.98M |
Ryvu Therapeutics | 97.57M |
Centrum Medyczne ENEL-MED | 762.83M |
Selvita | 359.79M |
EMC Instytut Medyczny | 836.81M |
Mercator Medical | 559.42M |
Celon Pharma News
- 3 months ago - Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - Benzinga